Bank of America upgraded Akero Therapeutics (NASDAQ:AKRO) on Thursday, citing what it called “game-changing” data the company disclosed from a mid-stage trial for its lead drug efruxifermin against ...

Jonathan Woo, an analyst from Phillip Securities, maintained the Buy rating on Akero Therapeutics (AKRO – Research Report). The associated ...

Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...

Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...

Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused ...

After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed ...

In the trial, dubbed SYMMETRY, Efruxifermin demonstrated statistically significant cirrhosis reversal in patients with biopsy-confirmed compensated cirrhosis due to metabolic dysfunction-associated ...

Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...

Akero Therapeutics, Inc. (NASDAQ:AKRO) released preliminary topline week 96 results from SYMMETRY Phase 2b study evaluating ...

Akero Therapeutics shares doubled to $55.64 in premarket trading after the company said it saw positive preliminary topline results from its Phase 2b study evaluating the efficacy and safety of its ...

Akero Therapeutics Inc (NASDAQ: AKRO) says its candidate treatment for a serious liver disease demonstrated exceptional ...

On Monday, at 10:23 a.m. GMT-5, Akero Therapeutics ( AKRO, Financials) saw its stock soar by 106.63%, closing at $54.10, ...